Novartis NVS announced that the FDA has approved breast cancer drug Kisqali (ribociclib) for a broader population.The regulatory body approved Kisqali in combination with an aromatase inhibitor (AI) for...
Novartis NVS announced positive data on breast cancer drug Kisqali (ribociclib) from the late-stage study, NATALEE.This late-breaking data from this four-year post-hoc analysis was presented at the European...
Eli Lilly and Company LLY announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, also called eczema. Ebglyss is approved...
Roche RHHBY announced that the FDA has approved the subcutaneous (SC) formulation of the blockbuster immunotherapy drug Tecentriq (atezolizumab).The SC formulation was approved under the brand name Tecentriq...
Large drug-maker stocks have witnessed a strong run this year, driven by positive pipeline news and regulatory approvals. The FDA has granted approval to 29 novel drugs this year. Innovation in the industry...
Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous urticaria (CSU)...
The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...
Bayer BAYRY announced positive results from the expansion part of the ongoing early to mid-stage study on pipeline candidate BAY 2927088.BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI)...
The Chart of the Day belongs to the Swiss pharmaceutical company Novartis (NVS) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals,...
/CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) applauds the work done by Muscular Dystrophy Canada and the provinces to ensure that every newborn in...